The Top 5 Biosimilars Articles for the Week of October 21

October 25, 2019

The Center for Biosimilars® recaps the top stories for the week of October 21, 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of October 21, 2019.

Number 5: The World Health Organization and the International Generic and Biosimilar Medicines Association have signed a memorandum of understanding on generics and biosimilars.

Number 4: Humana filed a lawsuit against more than 30 defendants whom it says engaged in a conspiracy to fix the prices of generic drugs.

Number 3: Researchers have now published detailed results from ABP 710’s phase 1 clinical study that evaluated the pharmacokinetic similarity of the biosimilar and reference infliximab.

Number 2: A recent survey of employers regarding their concerns about growing healthcare costs reveals that some are looking to biosimilars as one method of controlling specialty drug spending.

Number 1: During the United European Gastroenterology Week 2019 meeting, researchers presented results of a phase 1 pivotal study of a subcutaneously administered formulation of biosimilar infliximab, CT-P13, in patients with inflammatory bowel disease.

Finally, last week, our e-newsletter asked whether you think that you think that potential one-time therapies are likely to render high-cost eculizumab and its biosimilars less relevant.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.